Dr. Kuntz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
225 E. Chicago Ave
Box 51
Chicago, IL 60611Phone+1 507-284-2511
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Child Neurology, 1977 - 1980
- Johns Hopkins UniversityResidency, Pediatrics, 1975 - 1977
- Boston University School of MedicineClass of 1975
Certifications & Licensure
- IL State Medical License 2009 - 2026
- HI State Medical License 1986 - 2024
- WI State Medical License 2003 - 2011
- MN State Medical License 1999 - 2010
- American Board of Pediatrics Pediatrics
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2005 Dec 01
- Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Start of enrollment: 2010 Feb 01
- Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 360 citationsNusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda, Wuh-Liang Hwu, Thomas O. Crawford
Neuromuscular Disorders. 2019-09-12 - 258 citationsNatural history of infantile-onset spinal muscular atrophy.Stephen J. Kolb, Christopher S. Coffey, Jon W. Yankey, Kristin J. Krosschell, W. David Arnold
Annals of Neurology. 2017-12-01 - 632 citationsInternational consensus guidance for management of myasthenia gravis: Executive summaryDonald B. Sanders, Gil I. Wolfe, Michael Benatar, Amelia Evoli, Nils Erik Gilhus
Neurology. 2016-07-26
Press Mentions
- Novel Drug May Improve Treatment for Duchenne Muscular DystrophyNovember 9th, 2020
- SMA Economic, QoL Burden High in Pre-Treatment EraJune 12th, 2020
- Breakthrough Drug Offers Hope for Patients with Debilitating Muscular DiseaseDecember 7th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: